The Global Market for ADME-Toxicology Testing is Projected to Reach US$16.2 Billion by 2024

Growing Number of New Drugs Failing Phase II and III Clinical Trials Due to Toxicity Issues Drives the Focus on ADME-Toxicology Testing, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market size, and demand forecasts on the global ADME-Toxicology Testing market. The global market for ADME-Toxicology Testing is projected to reach US$16.2 billion by 2024, driven by the growing losses and writedowns related to drug failure in developmental stages due to unchecked and unaddressed toxicity issues and the resulting emphasis on integrating ADME-Toxicology Testing  in early preclinical drug development stage.

Predicting the safety profile of drugs during all stages of clinical development has been a major endeavor of pharmaceutical companies for decades. Yet, despite spending billions of dollars, non-clinical and clinical studies continue to show substantial variation in results on drug behavior, leading to significantly high attrition rate of drugs in clinical trials. While drug development costs have increased substantially over the years, the number of drugs newly approved has virtually stagnated – an apparent result of high drug attrition rate in development. The growing focus on minimizing costs while improving hit rates have elevated the importance of ADME-Toxicology testing, which help companies assess the pharmacological effect of the drug and the potential of the drug to induce toxicity in humans, respectively. Drug failures in late stage clinical development compelled pharmaceutical companies to focus on pushing toxicology testing further upstream in drug development process to drug discovery alongside ADME testing for preventing costly down the lane failures. Increasing number of potential drug targets, dearth of detailed information on these targets, increasing focus on reducing drug developmental costs, growing intent to detect potential ADME and Toxicological issues earlier in clinical development and growing number of drugs under development are the major factors driving growth in the market. With the testing moving towards early clinical development, such drug discovery and lead optimization stages, in-vitro toxicology testing is fast gaining prominence.

Technological advancements have contributed significantly to the changing paradigm in the ADME-Toxicology testing market. Increasing human comprehension of factors affecting drug behavior, driven in turn by advancements in genetics and other areas, has constantly driven evolution in ADME-Tox assays. The deployment of in-silico technologies, computational technologies, advanced informatics and sophisticated software solutions are further improving ADME-Tox testing. Technological breakthroughs have enabled use of cell lines, such as those of liver, for targeted hepatotoxicity testing, an approach unavailable until recent years. Further advancements in this direction are allowing the development of novel cell lines, and means to developing them, resembling the indications in humans. Use of cell systems based microtiters is beginning to blur the lines between ADME testing and toxicology testing. Drawbacks in cell lines-based ADME-Tox testing are leading to development of various other strategies, including co-culture, 3D and suspension, and immortalization. Emergence of three-dimensional cell cultures is, however, driving demand for advanced liquid-handling instruments. Focus is also gaining on developing cultures that can sustain longer durations are important to simulate chronic exposure of drugs. Acquisition and analysis software solutions that assist correlating structures with metabolism are fast gaining importance, and are witnessing considerable developments. However, there is still significant room for further technological developments for better human models in screening and assessing biotransformation of drugs in humans.

As stated by the new market research report on ADME-Toxicology Testing, the United States represents the largest market worldwide supported by stringent adherence to regulatory toxicology and pharmacology guidelines. Asia-Pacific ranks as the fastest growing market with a CAGR of 12% through the analysis period led by increased outsourcing of drug discovery, and clinical trials to low-cost countries particularly China and India; increasing partnerships between international pharma companies with research laboratories in the region along with rising support from regional governments.  

Major players in the market include ACEA Biosciences Inc., ADMEcell Inc., Agilent Technologies Inc., Albany Molecular Research Inc., Beckman Coulter Inc., Cerep SA, CompuDrug International Inc., Cyprotex PLC., CeeTox Inc., Dassault Systèmes Biovia Corp., Eurofins ADME BIOANALYSES SAS, Galapagos NV, Molecular Discovery Ltd., MultiCASE Inc., Optivia Biotechnology, PerkinElmer Inc., Promega Corporation, Qualyst Inc., Simulations Plus Inc., Takara Bio Europe AB, Tecan Group Ltd. and Thermo Fisher Scientific Inc. among others.

The research report titled “ADME-Toxicology Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for ADME-Toxicology Testing in value terms for all major geographic markets such as United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain and Rest of Europe), Asia-Pacific and Rest of World. Global and regional market analytics are further analyzed by the following testing categories/types: Toxicology Testing (In-Vivo and In-Vitro) and ADME Testing.

To connect with us, visit our LinkedIn page.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.